

## Information for Patient

BREYANZI may cause side effects that can lead to death.

**Call your oncologist or go to the emergency room right away if the following symptoms appear:**

- Fever (100.4°F/38°C or higher)
- Difficulty breathing
- Chills or shaking chills
- Confusion
- Dizziness or lightheadedness
- Severe nausea, vomiting, or diarrhea
- Fast or irregular heart rate
- Severe fatigue or weakness

BREYANZI® is a trademark of Juno Therapeutics, Inc., a Bristol-Myers Squibb Company.  
©2020 Juno Therapeutics, Inc., a Bristol-Myers Squibb Company. All Rights Reserved.



## Patient Wallet Card

**Have this card with you at all times. Show it to any doctor who sees you and when you go to the hospital.**

- Tell any healthcare provider who sees you that you are being treated with BREYANZI®.
- For at least 4 weeks after receiving BREYANZI, you should plan to stay within 2 hours of the location where you received treatment.
- Refrain from driving or operating heavy or potentially dangerous machines until at least 8 weeks after BREYANZI administration.

Name of BREYANZI Treating Oncologist

Office Phone Number

After-hours Phone Number

Hospital Name (for Management of BREYANZI Side Effects)

Date of BREYANZI Infusion

11/20 US-REMS-BRZ190003

[BreyanziREMS.com](https://www.breyanziREMS.com)

### Information for the Healthcare Provider

This patient has received BREYANZI CAR T cell therapy, a CD19-directed genetically modified autologous T cell immunotherapy.



**Following treatment with BREYANZI, Cytokine Release Syndrome (CRS) or neurologic toxicities may occur, which may be fatal or life-threatening. CRS may involve any organ system.**

### Contact Patient's Oncologist Immediately for Further Information and in the Following Situations:

- Before giving steroids or cytotoxic medications.
- If the patient has a serious infection.
- Before the patient undergoes an invasive procedure.